Renoprotective effects of a highly selective A3 adenosine receptor antagonist in a mouse model of adriamycin-induced nephropathy

Hye Sook Min, Jin Joo Cha, Kitae Kim, Jung Eun Kim, Jung Yeon Ghee, Hyunwook Kim, Ji Eun Lee, Jee Young Han, Lak Shin Jeong, Dae-Ryong Cha, Young Sun Kang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The concentration of adenosine in the normal kidney increases markedly during renal hypoxia, ischemia, and inflammation. A recent study reported that an A3 adenosine receptor (A3AR) antagonist attenuated the progression of renal fibrosis. The adriamycin (ADX)-induced nephropathy model induces podocyte injury, which results in severe proteinuria and progressive glomerulosclerosis. In this study, we investigated the preventive effect of a highly selective A3AR antagonist (LJ1888) in ADX-induced nephropathy. Three groups of six-week-old Balb/c mice were treated with ADX (11 mg/kg) for four weeks and LJ1888 (10 mg/kg) for two weeks as following: 1) control; 2) ADX; and 3) ADX + LJ1888. ADX treatment decreased body weight without a change in water and food intake, but this was ameliorated by LJ1888 treatment. Interestingly, LJ1888 lowered plasma creatinine level, proteinuria, and albuminuria, which had increased during ADX treatment. Furthermore, LJ1888 inhibited urinary nephrin excretion as a podocyte injury marker, and urine 8-isoprostane and kidney lipid peroxide concentration, which are markers of oxidative stress, increased after injection of ADX. ADX also induced the activation of proinflammatory and profibrotic molecules such as TGF-β1, MCP-1, PAI-1, type IV collagen, NF-κB, NOX4, TLR4, TNFα, IL-1β, and IFN-γ, but they were remarkably suppressed after LJ1888 treatment. In conclusion, our results suggest that LJ1888 has a renoprotective effect in ADX-induced nephropathy, which might be associated with podocyte injury through oxidative stress. Therefore, LJ1888, a selective A3AR antagonist, could be considered as a potential therapeutic agent in renal glomerular diseases which include podocyte injury and proteinuria.

Original languageEnglish
Pages (from-to)1403-1412
Number of pages10
JournalJournal of Korean Medical Science
Volume31
Issue number9
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Adenosine A3 Receptor Antagonists
Podocytes
Doxorubicin
Proteinuria
Kidney
8-epi-prostaglandin F2alpha
Wounds and Injuries
Oxidative Stress
Renal Agents
Therapeutics
Albuminuria
Collagen Type IV
Lipid Peroxides
Plasminogen Activator Inhibitor 1
Interleukin-1
Adenosine
Drinking
Creatinine
Fibrosis
Ischemia

Keywords

  • Adenosine receptor antagonist
  • Adriamycin
  • Mouse model
  • Nephropathy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Renoprotective effects of a highly selective A3 adenosine receptor antagonist in a mouse model of adriamycin-induced nephropathy. / Min, Hye Sook; Cha, Jin Joo; Kim, Kitae; Kim, Jung Eun; Ghee, Jung Yeon; Kim, Hyunwook; Lee, Ji Eun; Han, Jee Young; Jeong, Lak Shin; Cha, Dae-Ryong; Kang, Young Sun.

In: Journal of Korean Medical Science, Vol. 31, No. 9, 01.01.2016, p. 1403-1412.

Research output: Contribution to journalArticle

Min, Hye Sook ; Cha, Jin Joo ; Kim, Kitae ; Kim, Jung Eun ; Ghee, Jung Yeon ; Kim, Hyunwook ; Lee, Ji Eun ; Han, Jee Young ; Jeong, Lak Shin ; Cha, Dae-Ryong ; Kang, Young Sun. / Renoprotective effects of a highly selective A3 adenosine receptor antagonist in a mouse model of adriamycin-induced nephropathy. In: Journal of Korean Medical Science. 2016 ; Vol. 31, No. 9. pp. 1403-1412.
@article{862bcb3b0c0743ee9d89575f39d9c85e,
title = "Renoprotective effects of a highly selective A3 adenosine receptor antagonist in a mouse model of adriamycin-induced nephropathy",
abstract = "The concentration of adenosine in the normal kidney increases markedly during renal hypoxia, ischemia, and inflammation. A recent study reported that an A3 adenosine receptor (A3AR) antagonist attenuated the progression of renal fibrosis. The adriamycin (ADX)-induced nephropathy model induces podocyte injury, which results in severe proteinuria and progressive glomerulosclerosis. In this study, we investigated the preventive effect of a highly selective A3AR antagonist (LJ1888) in ADX-induced nephropathy. Three groups of six-week-old Balb/c mice were treated with ADX (11 mg/kg) for four weeks and LJ1888 (10 mg/kg) for two weeks as following: 1) control; 2) ADX; and 3) ADX + LJ1888. ADX treatment decreased body weight without a change in water and food intake, but this was ameliorated by LJ1888 treatment. Interestingly, LJ1888 lowered plasma creatinine level, proteinuria, and albuminuria, which had increased during ADX treatment. Furthermore, LJ1888 inhibited urinary nephrin excretion as a podocyte injury marker, and urine 8-isoprostane and kidney lipid peroxide concentration, which are markers of oxidative stress, increased after injection of ADX. ADX also induced the activation of proinflammatory and profibrotic molecules such as TGF-β1, MCP-1, PAI-1, type IV collagen, NF-κB, NOX4, TLR4, TNFα, IL-1β, and IFN-γ, but they were remarkably suppressed after LJ1888 treatment. In conclusion, our results suggest that LJ1888 has a renoprotective effect in ADX-induced nephropathy, which might be associated with podocyte injury through oxidative stress. Therefore, LJ1888, a selective A3AR antagonist, could be considered as a potential therapeutic agent in renal glomerular diseases which include podocyte injury and proteinuria.",
keywords = "Adenosine receptor antagonist, Adriamycin, Mouse model, Nephropathy",
author = "Min, {Hye Sook} and Cha, {Jin Joo} and Kitae Kim and Kim, {Jung Eun} and Ghee, {Jung Yeon} and Hyunwook Kim and Lee, {Ji Eun} and Han, {Jee Young} and Jeong, {Lak Shin} and Dae-Ryong Cha and Kang, {Young Sun}",
year = "2016",
month = "1",
day = "1",
doi = "10.3346/jkms.2016.31.9.1403",
language = "English",
volume = "31",
pages = "1403--1412",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "9",

}

TY - JOUR

T1 - Renoprotective effects of a highly selective A3 adenosine receptor antagonist in a mouse model of adriamycin-induced nephropathy

AU - Min, Hye Sook

AU - Cha, Jin Joo

AU - Kim, Kitae

AU - Kim, Jung Eun

AU - Ghee, Jung Yeon

AU - Kim, Hyunwook

AU - Lee, Ji Eun

AU - Han, Jee Young

AU - Jeong, Lak Shin

AU - Cha, Dae-Ryong

AU - Kang, Young Sun

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The concentration of adenosine in the normal kidney increases markedly during renal hypoxia, ischemia, and inflammation. A recent study reported that an A3 adenosine receptor (A3AR) antagonist attenuated the progression of renal fibrosis. The adriamycin (ADX)-induced nephropathy model induces podocyte injury, which results in severe proteinuria and progressive glomerulosclerosis. In this study, we investigated the preventive effect of a highly selective A3AR antagonist (LJ1888) in ADX-induced nephropathy. Three groups of six-week-old Balb/c mice were treated with ADX (11 mg/kg) for four weeks and LJ1888 (10 mg/kg) for two weeks as following: 1) control; 2) ADX; and 3) ADX + LJ1888. ADX treatment decreased body weight without a change in water and food intake, but this was ameliorated by LJ1888 treatment. Interestingly, LJ1888 lowered plasma creatinine level, proteinuria, and albuminuria, which had increased during ADX treatment. Furthermore, LJ1888 inhibited urinary nephrin excretion as a podocyte injury marker, and urine 8-isoprostane and kidney lipid peroxide concentration, which are markers of oxidative stress, increased after injection of ADX. ADX also induced the activation of proinflammatory and profibrotic molecules such as TGF-β1, MCP-1, PAI-1, type IV collagen, NF-κB, NOX4, TLR4, TNFα, IL-1β, and IFN-γ, but they were remarkably suppressed after LJ1888 treatment. In conclusion, our results suggest that LJ1888 has a renoprotective effect in ADX-induced nephropathy, which might be associated with podocyte injury through oxidative stress. Therefore, LJ1888, a selective A3AR antagonist, could be considered as a potential therapeutic agent in renal glomerular diseases which include podocyte injury and proteinuria.

AB - The concentration of adenosine in the normal kidney increases markedly during renal hypoxia, ischemia, and inflammation. A recent study reported that an A3 adenosine receptor (A3AR) antagonist attenuated the progression of renal fibrosis. The adriamycin (ADX)-induced nephropathy model induces podocyte injury, which results in severe proteinuria and progressive glomerulosclerosis. In this study, we investigated the preventive effect of a highly selective A3AR antagonist (LJ1888) in ADX-induced nephropathy. Three groups of six-week-old Balb/c mice were treated with ADX (11 mg/kg) for four weeks and LJ1888 (10 mg/kg) for two weeks as following: 1) control; 2) ADX; and 3) ADX + LJ1888. ADX treatment decreased body weight without a change in water and food intake, but this was ameliorated by LJ1888 treatment. Interestingly, LJ1888 lowered plasma creatinine level, proteinuria, and albuminuria, which had increased during ADX treatment. Furthermore, LJ1888 inhibited urinary nephrin excretion as a podocyte injury marker, and urine 8-isoprostane and kidney lipid peroxide concentration, which are markers of oxidative stress, increased after injection of ADX. ADX also induced the activation of proinflammatory and profibrotic molecules such as TGF-β1, MCP-1, PAI-1, type IV collagen, NF-κB, NOX4, TLR4, TNFα, IL-1β, and IFN-γ, but they were remarkably suppressed after LJ1888 treatment. In conclusion, our results suggest that LJ1888 has a renoprotective effect in ADX-induced nephropathy, which might be associated with podocyte injury through oxidative stress. Therefore, LJ1888, a selective A3AR antagonist, could be considered as a potential therapeutic agent in renal glomerular diseases which include podocyte injury and proteinuria.

KW - Adenosine receptor antagonist

KW - Adriamycin

KW - Mouse model

KW - Nephropathy

UR - http://www.scopus.com/inward/record.url?scp=84983486486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983486486&partnerID=8YFLogxK

U2 - 10.3346/jkms.2016.31.9.1403

DO - 10.3346/jkms.2016.31.9.1403

M3 - Article

C2 - 27510383

AN - SCOPUS:84983486486

VL - 31

SP - 1403

EP - 1412

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 9

ER -